{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:54Z","timestamp":1793830914166,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ygyno.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:16:45Z","timestamp":1773451005000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials"],"prefix":"10.1016","volume":"208","author":[{"given":"Alhasan","family":"Altayf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Chiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Fadeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamedhen Vall","family":"Nounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Abuasaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elgazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Shoulkamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0010","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1186\/s12889-022-13861-y","article-title":"The global burden and associated factors of ovarian cancer in 1990\u20132019: findings from the global burden of disease study 2019","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.ygyno.2026.03.002_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.ygyno.2026.03.002_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ygyno.2026.03.002_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.936","article-title":"The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer","volume":"5","author":"Mazidimoradi","year":"2022","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.ygyno.2026.03.002_bb0030","article-title":"Socioeconomic burden of ovarian cancer in 11 countries","volume":"11","author":"Hutchinson","year":"2025","journal-title":"JCO Glob. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.03.002_bb0035","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis","volume":"41","author":"Huo","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2026.03.002_bb0040","doi-asserted-by":"crossref","first-page":"1029976","DOI":"10.3389\/fonc.2022.1029976","article-title":"The current role of secondary cytoreductive surgery for recurrent ovarian cancer","volume":"12","author":"de Bree","year":"2022","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2026.03.002_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12227012","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): new approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis","volume":"12","author":"Della Corte","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050904","article-title":"Evaluating the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) on interval and secondary debulking in ovarian cancer: a systematic review","volume":"17","author":"Tsolakidis","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ygyno.2026.03.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17676","article-title":"Interval cytoreductive surgery and cisplatin- or paclitaxel-based HIPEC for advanced ovarian cancer","volume":"8","author":"Gonz\u00e1lez S\u00e1nchez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.03.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2024.102117","article-title":"A clinician\u2019s perspective on the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer management","volume":"56","author":"Ostrowski","year":"2024","journal-title":"Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.03.002_bb0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2026.03.002_bb0160","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.03.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110424","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: a systematic review and meta-analysis of randomized control trials","volume":"51","author":"Guerra","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0080","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1245\/s10434-025-16979-6","article-title":"Cytoreductive surgery plus HIPEC in recurrent or newly diagnosed advanced epithelial ovarian cancer: a meta-analysis","volume":"32","author":"Taliento","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.03.002_bb0085","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2026.03.002_bb0090","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J."},{"issue":"2","key":"10.1016\/j.ygyno.2026.03.002_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jrsm.1384","article-title":"Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example","volume":"11","author":"de Jong","year":"2020","journal-title":"Res. Synth. Methods"},{"issue":"21","key":"10.1016\/j.ygyno.2026.03.002_bb0100","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/sim.6556","article-title":"Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data","volume":"34","author":"Wei","year":"2015","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pst.2386","article-title":"Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance","volume":"23","author":"Siegel","year":"2024","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12874-022-01541-9","article-title":"Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane database of systematic reviews","volume":"22","author":"Salika","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"issue":"16","key":"10.1016\/j.ygyno.2026.03.002_bb0115","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.03.002_bb0120","author":"Veritas Health Innovation"},{"key":"10.1016\/j.ygyno.2026.03.002_bb0125","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0130","article-title":"A method for reconstructing individual patient data from Kaplan-Meier survival curves that incorporate marked censoring times","volume":"7","author":"Rogula","year":"2022","journal-title":"MDM Policy Pract."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2026.03.002_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.03.002_bb0145","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.03.002_bb0150","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian Cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"issue":"7","key":"10.1016\/j.ygyno.2026.03.002_bb0165","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian Cancer: a randomized trial on survival evaluation (HORSE; MITO-18)","volume":"43","author":"Fagotti","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.03.002_bb0170","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0175","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.03.002_bb0180","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051402","article-title":"Mechanistic insights on hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"15","author":"Huffman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2026.03.002_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0195","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","article-title":"Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma","volume":"105","author":"Helm","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010078","article-title":"Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review","volume":"11","author":"Helderman","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0205","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.03.002_bib221","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","article-title":"Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma","volume":"33","author":"Lemoine","year":"2017","journal-title":"International Journal of Hyperthermia"},{"issue":"6","key":"10.1016\/j.ygyno.2026.03.002_bb0210","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1245\/s10434-022-11429-z","article-title":"Repeat CRS\/HIPEC: it comes down to tumor biology and ability to achieve a complete CRS","volume":"29","author":"Votanopoulos","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","article-title":"Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma","volume":"16","author":"Feng","year":"2023","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.03.002_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J. Ovarian Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:35:13Z","timestamp":1793597713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826008449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S0090825826008449"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.03.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}